166 related articles for article (PubMed ID: 30231326)
1. Ultimate Precision: Targeting Cancer but Not Normal Self-replication.
Velcheti V; Schrump D; Saunthararajah Y
Am Soc Clin Oncol Educ Book; 2018 May; 38():950-963. PubMed ID: 30231326
[TBL] [Abstract][Full Text] [Related]
2. Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.
Velcheti V; Radivoyevitch T; Saunthararajah Y
Am Soc Clin Oncol Educ Book; 2017; 37():812-824. PubMed ID: 28561650
[TBL] [Abstract][Full Text] [Related]
3. Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells.
Enane FO; Saunthararajah Y; Korc M
Cell Death Dis; 2018 Sep; 9(9):912. PubMed ID: 30190481
[TBL] [Abstract][Full Text] [Related]
4. Stem cell plasticity in development and cancer: epigenetic origin of cancer stem cells.
Shah M; Allegrucci C
Subcell Biochem; 2013; 61():545-65. PubMed ID: 23150267
[TBL] [Abstract][Full Text] [Related]
5. [Master Transcription Regulators Specifying Cell-Lineage Fates in Development As Possible Therapeutic Targets in Oncology].
Kondratyeva LG; Vinogradova TV; Chernov IP; Sverdlov ED
Genetika; 2015 Nov; 51(11):1221-33. PubMed ID: 26845852
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells.
Jha BK; Saunthararajah Y
Semin Hematol; 2021 Jan; 58(1):1-3. PubMed ID: 33509437
[TBL] [Abstract][Full Text] [Related]
7. PBRM1 loss in kidney cancer unbalances the proximal tubule master transcription factor hub to repress proximal tubule differentiation.
Gu X; Enane F; Tohme R; Schuerger C; Radivoyevitch T; Parker Y; Zuberi E; Przychodzen B; Jha BK; Lindner D; Rini B; Saunthararajah Y
Cell Rep; 2021 Sep; 36(12):109747. PubMed ID: 34551289
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cells and "stemness" genes in neuro-oncology.
Nicolis SK
Neurobiol Dis; 2007 Feb; 25(2):217-29. PubMed ID: 17141509
[TBL] [Abstract][Full Text] [Related]
9. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis.
Celià-Terrassa T; Liu DD; Choudhury A; Hang X; Wei Y; Zamalloa J; Alfaro-Aco R; Chakrabarti R; Jiang YZ; Koh BI; Smith HA; DeCoste C; Li JJ; Shao ZM; Kang Y
Nat Cell Biol; 2017 Jun; 19(6):711-723. PubMed ID: 28530657
[TBL] [Abstract][Full Text] [Related]
10. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.
Zakaria N; Yusoff NM; Zakaria Z; Lim MN; Baharuddin PJ; Fakiruddin KS; Yahaya B
BMC Cancer; 2015 Feb; 15():84. PubMed ID: 25881239
[TBL] [Abstract][Full Text] [Related]
11. The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors.
Dani N; Olivero M; Mareschi K; van Duist MM; Miretti S; Cuvertino S; Patané S; Calogero R; Ferracini R; Scotlandi K; Fagioli F; Di Renzo MF
J Bone Miner Res; 2012 Jun; 27(6):1322-34. PubMed ID: 22367914
[TBL] [Abstract][Full Text] [Related]
12. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.
Krivtsov AV; Twomey D; Feng Z; Stubbs MC; Wang Y; Faber J; Levine JE; Wang J; Hahn WC; Gilliland DG; Golub TR; Armstrong SA
Nature; 2006 Aug; 442(7104):818-22. PubMed ID: 16862118
[TBL] [Abstract][Full Text] [Related]
13. Overlapping genes may control reprogramming of mouse somatic cells into induced pluripotent stem cells (iPSCs) and breast cancer stem cells.
Mosca E; Cocola C; Sabour D; Pelucchi P; Bertalot G; Palumbo O; Carella M; Götte M; Schöler HR; Reinbold R; Zucchi I; Milanesi L
In Silico Biol; 2010; 10(5-6):207-21. PubMed ID: 22430355
[TBL] [Abstract][Full Text] [Related]
14. Differentiation primary response genes and proto-oncogenes as positive and negative regulators of terminal hematopoietic cell differentiation.
Liebermann DA; Hoffman B
Stem Cells; 1994 Jul; 12(4):352-69. PubMed ID: 7951003
[TBL] [Abstract][Full Text] [Related]
15. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
[TBL] [Abstract][Full Text] [Related]
16. Developing Cures: Targeting Ontogenesis in Cancer.
Lin VTG; Pruitt HC; Samant RS; Shevde LA
Trends Cancer; 2017 Feb; 3(2):126-136. PubMed ID: 28718443
[TBL] [Abstract][Full Text] [Related]
17. HOXA5 Counteracts Stem Cell Traits by Inhibiting Wnt Signaling in Colorectal Cancer.
Ordóñez-Morán P; Dafflon C; Imajo M; Nishida E; Huelsken J
Cancer Cell; 2015 Dec; 28(6):815-829. PubMed ID: 26678341
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic approaches targeting cancer stem cells.
Pan Y; Ma S; Cao K; Zhou S; Zhao A; Li M; Qian F; Zhu C
J Cancer Res Ther; 2018; 14(7):1469-1475. PubMed ID: 30589025
[TBL] [Abstract][Full Text] [Related]
19. Stem cell origin of cancer and differentiation therapy.
Sell S
Crit Rev Oncol Hematol; 2004 Jul; 51(1):1-28. PubMed ID: 15207251
[TBL] [Abstract][Full Text] [Related]
20. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
